The vaccine-delivery technology is designed for activating immunological cells which are located immediately below the surface of the skin.
Previously, Hoey served as business development vice president at Boston-based PathoGenetix, where he secured more than $55m from US Government contracts and corporate strategic alliances, in addition to a series of equity financings.
The company said with Hoey’s appointment, it is establishing operations in Cambridge, Massachusetts, to expand access to global pharmaceutical partners and complement the research and development operations based in Queensland, Australia.
Vaxxas chairman Paul Kelly said the company is pleased that Hoey was attracted by the potential of Nanopatch to enable a new class of next generation vaccines.
"David’s ability to create strong partnering alliances and success in business strategy will be a great asset as Vaxxas capitalizes on the broad set of opportunities for its proprietary Nanopatch technology," Kelly added.
Vaxxas chief executive officer David Hoey said he is excited to advance the commercialization of the delivery technology and grow the company that has broad potential to impact the next generation of vaccines and immunotherapies.
"With the potential to elicit a 100-fold increase in immune response compared to conventional needle-and-syringe, Vaxxas’ Nanopatch platform has true game changing potential," Hoey added.